MedPath

Sino Biopharm's Garsorasib Approved in China for Advanced NSCLC

• Sino Biopharmaceutical's Garsorasib, a KRAS G12C inhibitor, has been approved in China for treating advanced non-small cell lung cancer (NSCLC). • Clinical trials demonstrated that Garsorasib significantly improved survival rates compared to existing treatment options for NSCLC patients. • This approval positions Garsorasib as a key precision-targeted therapy, potentially expanding to other cancer indications in the future.

Sino Biopharmaceutical has received approval in China to market Garsorasib, a KRAS G12C inhibitor, for the treatment of advanced non-small cell lung cancer (NSCLC). This approval offers a new therapeutic avenue for patients with limited treatment options.
Garsorasib demonstrated strong efficacy in clinical trials, showing a significant improvement in survival rates compared to other available treatments. The drug's approval marks a significant advancement in precision-targeted cancer therapies.

Clinical Efficacy

While specific data from the clinical trials were not detailed in the source, the approval indicates that Garsorasib met the regulatory efficacy standards for NSCLC treatment in China. Further studies may explore the drug's potential in other cancer indications.

Precision-Targeted Therapy

Garsorasib's mechanism as a KRAS G12C inhibitor allows it to target a specific genetic mutation present in a subset of NSCLC tumors. This precision-targeted approach aims to improve treatment outcomes while minimizing off-target effects.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Glecirasib Demonstrates Promising Efficacy in KRAS G12C Mutant NSCLC

Jacobio Pharma's glecirasib shows significant efficacy in treating KRAS G12C-mutated non-small cell lung cancer (NSCLC) in a pivotal Phase II trial.
The study revealed a 47.9% objective response rate, a median progression-free survival of 8.2 months, and a median overall survival of 13.6 months with glecirasib monotherapy.

Henlius Receives Approval for HLX10 in China, Expanding Oncology Portfolio

Shanghai Henlius has received approval in China for HLX10 (recombinant anti-PD-1 monoclonal antibody injection) for the treatment of certain cancers, marking a significant advancement in their oncology portfolio.
The approval of HLX10 provides a new treatment option for patients in China, addressing unmet medical needs in the oncology space.

Shandong Xinhua Pharmaceutical Receives Approval for Generic Cefuroxime Axetil Dispersible Tablets in China

Xincat Pharmaceutical, a subsidiary of Shandong Xinhua Pharmaceutical, has received approval from China’s National Medical Products Administration for its cefuroxime axetil dispersible tablets.
The approval confirms the quality and efficacy of Xincat Pharmaceutical's cefuroxime axetil dispersible tablets as a generic drug, expanding the company's market presence.

Hansoh Pharma's HS-20093 Receives Breakthrough Therapy Designation in China for Small Cell Lung Cancer

Hansoh Pharma's B7-H3-targeted antibody-drug conjugate, HS-20093, has been granted Breakthrough Therapy Designation by China’s National Medical Products Administration.
The designation is for the treatment of small cell lung cancer (SCLC), a disease with significant unmet medical need.

Sacituzumab Tirumotecan (Sac-TMT) Approved in China for Advanced TNBC

Kelun-Biotech's Sacituzumab tirumotecan (Sac-TMT) has received marketing approval in China for treating advanced or metastatic triple-negative breast cancer (TNBC).
The approval is based on the Phase III OptiTROP-Breast01 trial, which showed Sac-TMT significantly improved progression-free survival (PFS) and overall survival (OS) compared to chemotherapy.

SSY Group Receives China Approval for Cycloserine Capsules and Lornoxicam Injection

SSY Group has received approval from China's National Medical Products Administration for Cycloserine Capsules.
Cycloserine Capsules are indicated for the treatment of tuberculosis and urinary tract infections, addressing critical medical needs.

Daehwa Pharm's Oral Paclitaxel (Liporaxel) Approved in China for Gastric Cancer Treatment

Daehwa Pharm's Liporaxel, an oral formulation of paclitaxel, has received marketing approval from China's NMPA for treating gastric cancer.
Liporaxel utilizes Daehwa's DHLASED technology, offering improved convenience and safety compared to traditional intravenous paclitaxel.

Akeso's Ivonescimab Demonstrates Superiority Over Pembrolizumab in Lung Cancer Trial

Akeso's Ivonescimab showed a notable increase in progression-free survival compared to Merck's Keytruda (pembrolizumab) in a Phase III clinical trial for lung cancer.
The Ivonescimab group demonstrated better outcomes regardless of patient age, gender, or the presence of liver and brain metastasis.

Jacobio Pharma's Glecirasib Shows Promise in KRAS G12C-Mutated NSCLC

Jacobio Pharma's glecirasib demonstrated a confirmed objective response rate (cORR) of 47.9% in second-line non-small cell lung cancer (NSCLC) patients.
The Phase II registrational study of glecirasib showed a median progression-free survival (mPFS) of 8.2 months and a median overall survival (mOS) of 13.6 months.

Glecirasib Receives Breakthrough Therapy Designation in China for Pancreatic Cancer

Jacobio Pharma's glecirasib, a KRAS G12C inhibitor, has been granted Breakthrough Therapy Designation (BTD) by China's CDE for pancreatic cancer.
The BTD is specifically for patients with KRAS G12C-mutated pancreatic cancer who have progressed after frontline standard care.

Reference News

[1]
Sino Biopharm's Garsorasib Gains Approval in China | Markets Insider
markets.businessinsider.com · Nov 11, 2024

Sino Biopharmaceutical's KRAS G12C inhibitor, Garsorasib, approved in China for advanced non-small cell lung cancer, sho...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy